Abbott Laboratories ROA 2010-2025 | ABT
Current and historical return on assets (ROA) values for Abbott Laboratories (ABT) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Abbott Laboratories ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2025-03-31 | $13.50B | $0.00B | 23.61% |
| 2024-12-31 | $13.40B | $81.41B | 17.79% |
| 2024-09-30 | $5.77B | $74.36B | 7.87% |
| 2024-06-30 | $5.56B | $73.02B | 7.64% |
| 2024-03-31 | $5.63B | $72.47B | 7.74% |
| 2023-12-31 | $5.72B | $73.21B | 7.83% |
| 2023-09-30 | $5.16B | $72.09B | 7.03% |
| 2023-06-30 | $5.16B | $73.35B | 7.01% |
| 2023-03-31 | $5.80B | $73.79B | 7.86% |
| 2022-12-31 | $6.93B | $74.44B | 9.39% |
| 2022-09-30 | $7.89B | $72.80B | 10.65% |
| 2022-06-30 | $8.55B | $74.20B | 11.51% |
| 2022-03-31 | $7.73B | $74.01B | 10.43% |
| 2021-12-31 | $7.07B | $75.20B | 9.59% |
| 2021-09-30 | $7.24B | $73.80B | 9.91% |
| 2021-06-30 | $6.38B | $73.27B | 8.87% |
| 2021-03-31 | $5.72B | $72.79B | 8.09% |
| 2020-12-31 | $4.50B | $72.55B | 6.49% |
| 2020-09-30 | $3.38B | $69.04B | 4.96% |
| 2020-06-30 | $3.11B | $68.78B | 4.57% |
| 2020-03-31 | $3.58B | $66.78B | 5.27% |
| 2019-12-31 | $3.69B | $67.89B | 5.41% |
| 2019-09-30 | $3.29B | $68.54B | 4.85% |
| 2019-06-30 | $2.90B | $68.43B | 4.21% |
| 2019-03-31 | $2.62B | $67.61B | 3.82% |
| 2018-12-31 | $2.37B | $67.17B | 3.41% |
| 2018-09-30 | $0.89B | $71.64B | 1.23% |
| 2018-06-30 | $0.93B | $68.42B | 1.29% |
| 2018-03-31 | $0.48B | $70.91B | 0.66% |
| 2017-12-31 | $0.48B | $76.25B | 0.66% |
| 2017-09-30 | $2.10B | $72.25B | 3.15% |
| 2017-06-30 | $1.17B | $71.15B | 2.00% |
| 2017-03-31 | $1.50B | $70.89B | 2.96% |
| 2016-12-31 | $1.40B | $52.67B | 3.26% |
| 2016-09-30 | $1.37B | $39.50B | 3.42% |
| 2016-06-30 | $2.28B | $39.83B | 5.61% |
| 2016-03-31 | $2.45B | $39.64B | 5.87% |
| 2015-12-31 | $4.42B | $41.25B | 10.40% |
| 2015-09-30 | $4.56B | $41.73B | 10.72% |
| 2015-06-30 | $4.52B | $44.13B | 10.57% |
| 2015-03-31 | $4.20B | $43.10B | 9.99% |
| 2014-12-31 | $2.28B | $41.21B | 5.48% |
| 2014-09-30 | $1.97B | $42.51B | 4.67% |
| 2014-06-30 | $2.40B | $41.48B | 5.63% |
| 2014-03-31 | $2.41B | $41.66B | 5.61% |
| 2013-12-31 | $2.58B | $42.95B | 5.97% |
| 2013-09-30 | $3.04B | $44.13B | 6.17% |
| 2013-06-30 | $4.02B | $42.90B | 7.43% |
| 2013-03-31 | $5.27B | $42.69B | 8.96% |
| 2012-12-31 | $5.96B | $67.24B | 9.36% |
| 2012-09-30 | $6.53B | $63.26B | 10.54% |
| 2012-06-30 | $4.89B | $61.86B | 8.01% |
| 2012-03-31 | $5.11B | $62.42B | 8.36% |
| 2011-12-31 | $4.73B | $60.28B | 7.77% |
| 2011-09-30 | $4.55B | $59.63B | 7.47% |
| 2011-06-30 | $5.14B | $62.00B | 8.51% |
| 2011-03-31 | $4.49B | $61.65B | 7.71% |
| 2010-12-31 | $4.63B | $60.57B | 8.24% |
| 2010-09-30 | $4.73B | $57.37B | 8.72% |
| 2010-06-30 | $5.31B | $53.38B | 10.16% |
| 2010-03-31 | $5.31B | $53.36B | 10.44% |
| 2009-12-31 | $5.75B | $52.58B | 11.76% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $227.162B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $140.689B | 37.90 |
| Stryker (SYK) | United States | $132.255B | 28.42 |
| EssilorLuxottica (ESLOY) | France | $128.431B | 0.00 |
| Medtronic (MDT) | Ireland | $105.938B | 15.47 |
| Lonza Group Ag (LZAGY) | Switzerland | $47.424B | 0.00 |
| Haleon (HLN) | United Kingdom | $46.151B | 26.20 |
| ResMed (RMD) | United States | $31.269B | 24.08 |
| Agilent Technologies (A) | United States | $29.217B | 19.30 |
| GE HealthCare Technologies (GEHC) | United States | $28.556B | 13.89 |
| Terumo (TRUMY) | Japan | $28.160B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $22.192B | 15.85 |
| Zimmer Biomet Holdings (ZBH) | United States | $19.373B | 12.24 |
| Insulet (PODD) | United States | $17.332B | 74.11 |
| Baxter (BAX) | United States | $14.818B | 10.66 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.356B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $7.609B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.938B | 17.06 |
| Bio-Rad Laboratories (BIO) | United States | $6.672B | 23.10 |
| Demant (WILYY) | Denmark | $6.644B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.977B | 18.98 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Perrigo (PRGO) | Ireland | $3.455B | 9.89 |
| ICU Medical (ICUI) | United States | $3.400B | 29.07 |
| Haemonetics (HAE) | United States | $2.872B | 13.52 |
| Envista Holdings (NVST) | United States | $2.614B | 20.80 |
| GN Store Nord (GNNDY) | Denmark | $2.188B | 14.75 |
| LeMaitre Vascular (LMAT) | United States | $1.946B | 44.47 |
| QuidelOrtho (QDEL) | United States | $1.698B | 14.22 |
| AtriCure (ATRC) | United States | $1.565B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.214B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.189B | 18.67 |
| AdaptHealth (AHCO) | United States | $1.051B | 10.12 |
| BioLife Solutions (BLFS) | United States | $1.041B | 0.00 |
| InMode (INMD) | Israel | $1.038B | 8.67 |
| Neogen (NEOG) | United States | $0.953B | 12.19 |
| Phibro Animal Health (PAHC) | United States | $0.700B | 10.74 |
| Evolus (EOLS) | United States | $0.686B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.649B | 0.00 |
| Valneva SE (VALN) | France | $0.552B | 0.00 |
| Owens & Minor (OMI) | United States | $0.535B | 4.56 |
| CeriBell (CBLL) | United States | $0.532B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.514B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.453B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.450B | 0.00 |
| Surmodics (SRDX) | United States | $0.394B | 0.00 |
| Omeros (OMER) | United States | $0.394B | 0.00 |
| SNDL (SNDL) | Canada | $0.368B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.329B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.328B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.302B | 13.07 |
| Viemed Healthcare (VMD) | United States | $0.262B | 23.68 |
| Sanara MedTech (SMTI) | United States | $0.262B | 0.00 |
| ZimVie (ZIMV) | United States | $0.261B | 15.65 |
| Sanuwave Health (SNWV) | United States | $0.256B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.251B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.250B | 44.40 |
| Cerus (CERS) | United States | $0.242B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.224B | 0.00 |
| Quanterix (QTRX) | United States | $0.200B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.189B | 0.00 |
| High Tide (HITI) | Canada | $0.187B | 0.00 |
| Biote (BTMD) | United States | $0.181B | 4.12 |
| TriSalus Life Sciences (TLSI) | United States | $0.175B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.172B | 13.24 |
| Brainsway (BWAY) | Israel | $0.155B | 48.47 |
| Jin Medical (ZJYL) | China | $0.147B | 0.00 |
| Organigram Global (OGI) | Canada | $0.135B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.123B | 15.42 |
| Agape ATP (ATPC) | $0.094B | 0.00 | |
| Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.086B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.083B | 0.00 |
| Exagen (XGN) | United States | $0.080B | 0.00 |
| MacroGenics (MGNX) | United States | $0.079B | 0.00 |
| Veru (VERU) | United States | $0.078B | 0.00 |
| Fonar (FONR) | United States | $0.076B | 10.65 |
| Zynex (ZYXI) | United States | $0.066B | 24.22 |
| United Health Products (UEEC) | United States | $0.065B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| InterCure (INCR) | Israel | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.049B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 11.61 |
| Apyx Medical (APYX) | United States | $0.037B | 0.00 |
| Modular Medical (MODD) | United States | $0.036B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.035B | 51.50 |
| Safety Shot (SHOT) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.021B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.010B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |